Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Product Name | NLRC3 |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | CARD15-like antibody CARD15-like protein antibody Caterpiller 16.2 antibody Caterpiller protein 16.2 antibody CLR16.2 antibody FLJ00348 antibody NLR family CARD domain containing 3 antibody Nlrc3 antibody NLRC3_HUMAN antibody NOD-like receptor C3 antibody NOD3 antibody NOD3 protein antibody Nucleotide-binding oligomerization domain protein 3 antibody Nucleotide-binding oligomerization domain protein 3 caterpiller 16.2 antibody nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain containing 3 antibody Protein NLRC3 antibody |
| Product description | Negative regulator of the innate immune response. Attenuates signaling pathways activated by Toll-like receptors (TLRs) and the DNA sensor STING/TMEM173 in response to pathogen-associated molecular patterns, such as intracellular poly(dA:dT), but not poly(I:C), or in response to DNA virus infection, including that of Herpes simplex virus 1 (HSV1) . May affect TLR4 signaling by acting at the level of TRAF6 ubiquitination, decreasing the activating 'Lys-63'-linked ubiquitination and leaving unchanged the degradative 'Lys-48'-linked ubiquitination. Inhibits the PI3K-AKT-mTOR pathway possibly by directly interacting with the posphatidylinositol 3-kinase regulatory subunit p85 (PIK3R1/PIK3R2) and disrupting the association between PIK3R1/PIK3R2 and the catalytic subunit p110 (PIK3CA/PIK3CB/PIK3CD) and reducing PIK3R1/PIK3R2 activation. Via its regulation of the PI3K-AKT-mTOR pathway, controls cell proliferation, predominantly in intestinal epithelial cells. |
| Immunogen | Peptide. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | ICCIHCFC |
| ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:100 |
|
| Species Reactivity | HumanMouse |
| Concentration | 1mg/ml |
| Alternative Names | CARD15-like antibody
CARD15-like protein antibody
Caterpiller 16.2 antibody
Caterpiller protein 16.2 antibody
CLR16.2 antibody
FLJ00348 antibody
NLR family CARD domain containing 3 antibody
Nlrc3 antibody
NLRC3_HUMAN antibody
NOD-like receptor C3 antibody
NOD3 antibody
NOD3 protein antibody
Nucleotide-binding oligomerization domain protein 3 antibody
Nucleotide-binding oligomerization domain protein 3 caterpiller 16.2 antibody
nucleotide-binding oligomerization domain leucine rich repeat and CARD domain containing 3 antibody Protein NLRC3 antibody |
|---|---|
| Molecular Weight(MW) | 114 kDa |
| Cellular Localization | Cytoplasm. |
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig7: Flow cytometric analysis of MCF-7 cells with NLRC3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Positive Control | MCF-7, SH-SY5Y, human tonsil tissue, human colon cancer tissue, human spleen tissue, mouse colon tissue. |
|---|---|
| Application Notes | ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
